After learning of the allegations, the drugmaker said it immediately hired external counsel to perform an independent investigation. The probe revealed consensual yet inappropriate personal communications between Mr. Smiley and some Eli Lilly employees, according to CNBC.
Eli Lilly said the communications constituted poor judgment from Mr. Smiley, but it has not disclosed how many employees were involved.
The drugmaker also said Mr. Smiley will be replaced by Anat Ashkenazi, who most recently served as the senior vice president, controller and CFO of its research laboratories arm.
Mr. Smiley, who has worked at Eli Lilly since 1995 and became its CFO in 2018, will assist with the transition of the CFO role through July at a reduced compensation of $9,000 every two weeks, the drugmaker said.
More articles on pharmacy:
More than 800 drug prices increased in January by an average of nearly 5%
UAB Medicine hospital launches retail pharmacy
AstraZeneca’s vaccine may not effectively protect against South Africa variant, small trial shows
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
